Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
Tumor-infiltrating lymphocytes (TIL) are considered enriched for T cells recognizing shared tumor antigens or mutation-derived neoepitopes. We performed exome sequencing and HLA-A*02:01 epitope prediction from tumor cell lines from two HLA-A2-positive melanoma patients whose TIL displayed strong tum...
Main Authors: | Stina L. Wickström, Tanja Lövgren, Michael Volkmar, Bruce Reinhold, Jonathan S. Duke-Cohan, Laura Hartmann, Janina Rebmann, Anja Mueller, Jeroen Melief, Roeltje Maas, Maarten Ligtenberg, Johan Hansson, Rienk Offringa, Barbara Seliger, Isabel Poschke, Ellis L. Reinherz, Rolf Kiessling |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.02766/full |
Similar Items
-
Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
by: Mary A. Wood, et al.
Published: (2020-03-01) -
An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes
by: Anne-Mette Bjerregaard, et al.
Published: (2017-11-01) -
Corrigendum: An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes
by: Anne-Mette Bjerregaard, et al.
Published: (2018-05-01) -
Population-level distribution and putative immunogenicity of cancer neoepitopes
by: Mary A. Wood, et al.
Published: (2018-04-01) -
Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
by: Eric de Sousa, et al.
Published: (2021-07-01)